Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

Markku Laakso; Julio Rosenstock; Per-Henrik Groop; Anthony H. Barnett; Baptist Gallwitz; Uwe Hehnke; Ilkka Tamminen; Sanjay Patel; Maximilian von Eynatten; Hans-Juergen Woerle

doi:10.2337/dc14-1684

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

Diabetes Care ◽

10.2337/dc14-1684 ◽

2015 ◽

Vol 38 (2) ◽

pp. e15-e17 ◽

Cited By ~ 27

Author(s):

Markku Laakso ◽

Julio Rosenstock ◽

Per-Henrik Groop ◽

Anthony H. Barnett ◽

Baptist Gallwitz ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Double Blind Clinical Trial

Download Full-text

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13574 ◽

2019 ◽

Vol 21 (4) ◽

pp. 781-790 ◽

Cited By ~ 8

Author(s):

Ronan Roussel ◽

Santiago Duran‐García ◽

Yilong Zhang ◽

Suneri Shah ◽

Carolyn Darmiento ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Glargine ◽

Randomized Clinical Trial ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1335637 ◽

2017 ◽

Vol 33 (10) ◽

pp. 1853-1860 ◽

Cited By ~ 7

Author(s):

R. Ravi Shankar ◽

Silvio E. Inzucchi ◽

Victoria Scarabello ◽

Ira Gantz ◽

Keith D. Kaufman ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Metformin Monotherapy ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.06.005 ◽

2011 ◽

Vol 33 (7) ◽

pp. 973-989 ◽

Cited By ~ 30

Author(s):

Yoshiharu Horie ◽

Shigeto Kanada ◽

Hirotaka Watada ◽

Akiko Sarashina ◽

Atsushi Taniguchi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Diabetes Patients

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.007 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1556-1568 ◽

Cited By ~ 354

Author(s):

Julio Rosenstock ◽

Ronald Brazg ◽

Paula J. Andryuk ◽

Kaifeng Lu ◽

Peter Stein

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Parallel Group Study ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Parallel Group

Download Full-text

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14107 ◽

2020 ◽

Vol 22 (10) ◽

pp. 1847-1856

Author(s):

Jordan Kraaijenhof ◽

Marcel H. A. Muskiet ◽

Lennart Tonneijck ◽

D. Margriet Ouwens ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2006.00704.x ◽

2007 ◽

Vol 9 (2) ◽

pp. 194-205 ◽

Cited By ~ 432

Author(s):

M. A. Nauck ◽

G. Meininger ◽

D. Sheng ◽

L. Terranella ◽

P. P. Stein ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.03.004 ◽

2008 ◽

Vol 30 (3) ◽

pp. 499-512 ◽

Cited By ~ 90

Author(s):

P COVINGTON ◽

R CHRISTOPHER ◽

M DAVENPORT ◽

P FLECK ◽

Q MEKKI ◽

...

Keyword(s):

Type 2 Diabetes ◽

Multiple Dose ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Multiple Dose Study ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Dose Study

Download Full-text

P2366 Atorvastatin in patients with type 2 diabetes on haemodialysis: design and patient characteristics of a double-blind clinical trial (die deutsche diabetes dialyse study)

European Heart Journal ◽

10.1016/s0195-668x(03)95360-7 ◽

2003 ◽

Vol 24 (5) ◽

pp. 461

Author(s):

W MARZ

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Patient Characteristics ◽

Double Blind ◽

Double Blind Clinical Trial

Download Full-text